Tag: Eli Lilly and Co

Here’s an update on our 4th Industrial Revolution stocks and the rest of the portfolio

Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial

Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China

Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start

Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs

Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections

White House to launch direct-to-consumer drug site Trump Rx. Here’s what to know